Company intelligence / Profile preview

Phycobloom

London, England, United Kingdomphycobloom.com ↗

Ownership: Private
Employees: ~11
Development stage: Other

Overview

Phycobloom has developed proprietary strains of microalgae that are genetically engineered to secrete oils directly, enabling scalable and cost-effective production of algae-based biofuels. Their technology eliminates costly extraction steps and aims to provide sustainable alternatives to fossil fuels for heavy transport sectors such as aviation and shipping. They are currently building prototypes with the goal of commercial deployment by 2030.

Modalities: Microbial therapySynthetic biology platform
Industry: Non-Drug Biotech

Partnerships

Happiness Capital

Beyond the preview

Go deeper on Phycobloom.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phycobloom.

Explore the full profile